Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Little sedi action.

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Feb 27, 2023 9:13am

90 Views

Post# 35306772

RE:RE:Little sedi action.

Seagen (ticker: SGEN) is currently valued at about $30 billion and a buyout would likely require a premium to that. The talks are still at an early stage and there is no guarantee of a transaction, the report said, citing unidentified people familiar with the situation.

2+ billions buyout of oncy is not out because of this negociation. Could be the opposite. We will see.

<< Previous

Bullboard Posts

Next >>

Odd Burger to add 40 locations in Florida